A Human Trial to Evaluate the Efficacy and Safety of Aged Garlic Powder on Improvement of Blood Lipids in Subjects With Hyperlipidemia

Chonbuk National University Hospital60 enrolled

Overview

We performed a double-blind parallel study in a group of mildly hypercholesterolemic subjects who were given aged garlic powder over a period of 12 weeks. We measured serum lipids, including total cholesterol, low-density-lipoprotein (LDL) and high-density-lipoprotein (HDL) cholesterol, and triglycerides, and monitored their blood pressure.

An increased serum cholesterol level is an important risk factor for the development of cardiovascular and cerebrovascular disease. Reduction of these and other risk factors through dietary modification, behavioral changes, and medicinal intervention has already substantially decreased the incidence and mortality from cardiovascular and cerebrovascular disease. Supplementation of the diet with certain biofactors may further reduce such risk factors. Aged garlic belongs to a group of dietary supplements that may lessen the incidence of cardiovascular and cerebrovascular disease by reducing lipids levels and decreasing platelet responsiveness to activating agents.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

SUPPORTIVE_CARE

Masking

DOUBLE

Enrollment

Conditions

Hyperlipidemia

Interventions

Aged garlic powderDIETARY_SUPPLEMENT

Aged garlic powder(6.0g/day)

Placebo powderDIETARY_SUPPLEMENT

Placebo powder(6.0g/day)

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Mild hypercholesterolemic subjects aged from 20 to 80 years * had no received lipid-lowering drugs for at least 3 months prior to the recruitment Exclusion Criteria: * self-reported pregnancy,lactation * prevalent heart disease,cancer,renal disorder, or diabetes mellitus, and use of lipid or antihypertensive medications

Locations (1)

Clinical Trial Center for Functional Foods; Chonbuk National University Hospital

Jeonju, Jeollabuk-do, South Korea

Outcomes

Primary Outcomes

Changes in LDL-cholesterol(Low Density Lipoprotein - Cholesterol)

LDL-C(Low Density Lipoprotein - cholesterol) was measured in study visit 1(0 week) and visit 3(12 week).

Time frame: 12 weeks

Secondary Outcomes

Changes in HDL-Cholesterol(High Density Lipoprotein - Cholesterol)

HDL-cholesterol(High Density Lipoprotein - cholesterol) was measured in study visit 1(0 week) and visit 3(12 week).

Time frame: 12 weeks

Changes in Triglycerides

Triglyceride was measured in study visit 1(0 week) and visit 3(12 week).

Time frame: 12 weeks

Changes in Total Cholesterol

Total cholesterol was measured in study visit 1(0 week) and visit 3(12 week).

Time frame: 12 weeks

Changes in Apo-A1(Apolipoprotein A1)

Apo-A1(Apolipoprotein A1) was measured in study visit 1(0 week) and visit 3(12 week).

Time frame: 12 weeks

Changes in Apo-B(Apolipoprotein B)

Apo-B(Apolipoprotein B) was measured in study visit 1(0 week) and visit 3(12 week).

Time frame: 12 weeks

Changes in FFA(Free Fatty Acid)

FFA(free fatty acid) was measured in study visit 1(0 week) and visit 3(12 week).

Time frame: 12 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.